Lund, Sweden and Seattle Washington, December 15, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) (NASDAQ: A ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") has completed the rights issue of ordinary shares (the "Ri ...

Alligator Bioscience AB (publ) ("Alligator" or the "Company") announces that the Company’s rights issue of shares (the “Righ ...

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1 L ...

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tu ...

Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastat ...

Data support Advancement into the Clinic Lund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and ...

Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rig ...